葛兰素史克Glaxosmithkline（GSK）2025年第一季度产品线资产及临床试验报告「LSE」（英文版）（97页）.pdf

1、Pipeline assets and clinical trials appendixQ1 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesInfectious disease3Innovation:Pipeline growthOverview of potential new vaccines and medicinesHIVHIVOncolog

2、yOncologyInfectious DiseasesInfectious DiseasesGlossaryGlossaryInnovation:Pipeline growthRIIRI&IRI&IOncologyHIVInfectious DiseasesPhase III/RegistrationPhase III/Registration18)camlipixant(GSK5464714)P2X3 receptor antagonistRefractory chronic coughdepemokimab(GSK3511294)Long-acting anti-IL5 antibody

3、*Asthma*latozinemab(GSK4527223)Anti-sortilin antibody*Frontotemporal dementia1linerixibat(GSK2330672)IBAT inhibitorCholestatic pruritus in primary biliary cholangitisLow carbon version of MDI2,Ventolin(salbutamol)Beta 2 adrenergic receptor agonistAsthmaNucala(mepolizumab)Anti-IL5 antibodyCOPD3belres

4、totug(GSK4428859)Anti-TIGIT antibody*Non-small cell lung cancer*Blenrep(belantamab mafodotin)Anti-BCMA ADC*Multiple myelomacobolimab(GSK4069889)Anti-TIM-3 antibody*Non-small cell lung cancerJemperli(dostarlimab)Anti-PD-1 antibody*dMMR/MSI-H colon cancer*Zejula(niraparib)PARP inhibitor*Ovarian cancer

5、*Arexvy(RSV vaccine)Recombinant protein,adjuvanted*RSV adults(18-49 YoA4 AIR5)*bepirovirsen(GSK3228836)Antisense oligonucleotide*Chronic HBV6 infection*Bexsero(MenB vaccine)Recombinant protein,OMVMeningitis B(infants US)Blujepa(gepotidacin)BTI inhibitor*Uncomplicated UTI7*GSK4178116Live,attenuatedVa

6、ricella new strainibrexafungerp(GSK5458448)Antifungal glucan synthase inhibitor*Invasive candidiasistebipenem pivoxil(GSK3778712)Antibacterial carbapenem*Complicated UTI74*In-license or other alliance relationship with third party *Additional indications or candidates also under investigation In reg